1. High Efficacy and Drug Synergy of HDAC6-Selective Inhibitor NN-429 in Natural Killer (NK)/T-Cell Lymphoma.
- Author
-
Garcha, Harsimran Kaur, Nawar, Nabanita, Sorger, Helena, Erdogan, Fettah, Aung, Myint Myat Khine, Sedighi, Abootaleb, Manaswiyoungkul, Pimyupa, Seo, Hyuk-Soo, Schönefeldt, Susann, Pölöske, Daniel, Dhe-Paganon, Sirano, Neubauer, Heidi A., Mustjoki, Satu M., Herling, Marco, de Araujo, Elvin D., Moriggl, Richard, and Gunning, Patrick T.
- Subjects
DRUG synergism ,DRUG efficacy ,HEMATOLOGIC malignancies ,LYMPHOMAS ,DEACETYLASES - Abstract
NK/T-cell lymphoma (NKTCL) and γδ T-cell non-Hodgkin lymphomas (γδ T-NHL) are highly aggressive lymphomas that lack rationally designed therapies and rely on repurposed chemotherapeutics from other hematological cancers. Histone deacetylases (HDACs) have been targeted in a range of malignancies, including T-cell lymphomas. This study represents exploratory findings of HDAC6 inhibition in NKTCL and γδ T-NHL through a second-generation inhibitor NN-429. With nanomolar in vitro HDAC6 potency and high in vitro and in cellulo selectivity for HDAC6, NN-429 also exhibited long residence time and improved pharmacokinetic properties in contrast to older generation inhibitors. Following unique selective cytotoxicity towards γδ T-NHL and NKTCL, NN-429 demonstrated a synergistic relationship with the clinical agent etoposide and potential synergies with doxorubicin, cytarabine, and SNS-032 in these disease models, opening an avenue for combination treatment strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF